HBK Investments L P Takes Position in Tempus AI, Inc. (NASDAQ:TEM)

HBK Investments L P purchased a new stake in shares of Tempus AI, Inc. (NASDAQ:TEM - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 150,000 shares of the company's stock, valued at approximately $5,064,000. HBK Investments L P owned about 0.10% of Tempus AI at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Nebula Research & Development LLC acquired a new position in Tempus AI in the fourth quarter valued at about $451,000. Stifel Financial Corp increased its stake in Tempus AI by 935.1% during the fourth quarter. Stifel Financial Corp now owns 39,810 shares of the company's stock worth $1,344,000 after purchasing an additional 35,964 shares during the period. Covalis Capital LLP purchased a new stake in Tempus AI during the fourth quarter worth about $1,688,000. Freedom Investment Management Inc. purchased a new stake in Tempus AI during the fourth quarter worth about $296,000. Finally, Blue Water Life Science Advisors LP purchased a new stake in Tempus AI during the fourth quarter worth about $3,038,000. Institutional investors and hedge funds own 24.22% of the company's stock.

Tempus AI Stock Performance

Shares of Tempus AI stock traded down $2.76 on Wednesday, reaching $51.53. 5,869,870 shares of the stock were exchanged, compared to its average volume of 5,694,188. Tempus AI, Inc. has a 1-year low of $22.89 and a 1-year high of $91.45. The company has a current ratio of 2.69, a quick ratio of 2.55 and a debt-to-equity ratio of 8.17. The business has a fifty day moving average price of $48.83 and a two-hundred day moving average price of $50.54.

Insider Transactions at Tempus AI

In other Tempus AI news, Director Wayne A.I. Frederick sold 3,000 shares of the company's stock in a transaction dated Monday, March 31st. The shares were sold at an average price of $45.54, for a total transaction of $136,620.00. Following the transaction, the director now directly owns 26,514 shares in the company, valued at approximately $1,207,447.56. This represents a 10.16 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CAO Ryan M. Bartolucci sold 13,770 shares of the company's stock in a transaction dated Friday, January 31st. The stock was sold at an average price of $60.00, for a total transaction of $826,200.00. Following the transaction, the chief accounting officer now owns 57,237 shares in the company, valued at $3,434,220. The trade was a 19.39 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 4,505,134 shares of company stock worth $268,609,285 over the last ninety days. 27.60% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

A number of analysts have issued reports on the stock. Needham & Company LLC reiterated a "buy" rating and set a $70.00 price target on shares of Tempus AI in a research note on Thursday, April 24th. Guggenheim restated a "buy" rating on shares of Tempus AI in a research note on Tuesday, February 25th. Morgan Stanley upped their target price on shares of Tempus AI from $50.00 to $60.00 and gave the stock an "overweight" rating in a research note on Thursday, March 6th. Loop Capital cut their target price on shares of Tempus AI from $57.00 to $52.00 and set a "buy" rating on the stock in a research note on Tuesday, January 14th. Finally, JPMorgan Chase & Co. lowered shares of Tempus AI from an "overweight" rating to a "neutral" rating and upped their target price for the stock from $50.00 to $55.00 in a research note on Tuesday, February 25th. Six investment analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $61.08.

Tempus AI Company Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.